血管紧张素转换酶抑制剂加中度限制膳食钠摄入与双联阻断在减少蛋白尿和降低血压方面的比较：随机对照试验

Objective:To compare the effects on proteinuria and blood pressure of addition of dietary sodium restriction or angiotensin receptor blockade at maximum dose, or their combination, in patients with non-diabetic nephropathy receiving background treatment with angiotensin converting enzyme (ACE) inhibition at maximum dose. Design:Multicentre crossover randomised controlled trial. Setting:Outpatient clinics in the Netherlands. Participants:52 patients with non-diabetic nephropathy. Interventions:All patients were treated during four 6week periods, in random order, with angiotensin receptor blockade (valsartan 320mg/day) or placebo, each combined with, consecutively, a low sodium diet (target 50mmol Na+/day) and a regular sodium diet (target 200mmol Na+/day), with a background of ACE inhibition (lisinopril 40mg/day) during the entire study. The drug interventions were double blind; the dietary interventions were open label. Main Outcome Measures:The primary outcome measure was proteinuria; the secondary outcome measure was blood pressure. Results:Mean urinary sodium excretion, a measure of dietary sodium intake, was 106 (SE 5) mmol Na+/day during a low sodium diet and 184 (6)mmol Na(+)/day during a regular sodium diet (P<0.001). Geometric mean residual proteinuria was 1.68 (95% confidence interval 1.31 to 2.14)g/day during ACE inhibition plus a regular sodium diet. Addition of angiotensin receptor blockade to ACE inhibition reduced proteinuria to 1.44 (1.07 to 1.93)g/day (P=0.003), addition of a low sodium diet reduced it to 0.85 (0.66 to 1.10)g/day (P<0.001), and addition of angiotensin receptor blockade plus a low sodium diet reduced it to 0.67 (0.50 to 0.91)g/day (P<0.001). The reduction of proteinuria by the addition of a low sodium diet to ACE inhibition (51%, 95% confidence interval 43% to 58%) was significantly larger (P<0.001) than the reduction of proteinuria by the addition of angiotensin receptor blockade to ACE inhibition (21%, (8% to 32%) and was comparable (P=0.009, not significant after Bonferroni correction) to the reduction of proteinuria by the addition of both angiotensin receptor blockade and a low sodium diet to ACE inhibition (62%, 53% to 70%). Mean systolic blood pressure was 134 (3)mmHg during ACE inhibition plus a regular sodium diet. Mean systolic blood pressure was not significantly altered by the addition of angiotensin receptor blockade (131 (3)mmHg; P=0.12) but was reduced by the addition of a low sodium diet (123 (2)mmHg; P<0.001) and angiotensin receptor blockade plus a low sodium diet (121 (3)mmHg; P<0.001) to ACE inhibition. The reduction of systolic blood pressure by the addition of a low sodium diet (7% (SE 1%)) was significantly larger (P=0.003) than the reduction of systolic blood pressure by the addition of angiotensin receptor blockade (2% (1)) and was similar (P=0.14) to the reduction of systolic blood pressure by the addition of both angiotensin receptor blockade and low sodium diet (9% (1)), to ACE inhibition. Conclusions:Dietary sodium restriction to a level recommended in guidelines was more effective than dual blockade for reduction of proteinuria and blood pressure in non-diabetic nephropathy. The findings support the combined endeavours of patients and health professionals to reduce sodium intake. Trial Registration:Netherlands Trial Register NTR675.